Bellicum Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Bellicum Pharmaceuticals, Inc.‘s stocks are currently a part of 22 hedge funds’ portfolios, which represents 15.1% of the total amount of its stocks outstanding. This makes up a total of 1.73M shares of Bellicum Pharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 18.33% or 269.16K shares more. As for the holding position changes, 22.73% (5) of current hedge fund investors increased the number of shares held, 13.64% (3) of current holders sold a part of the shares held, and 4.55% (1) closed the holdings completely. 6 hedge funds are new holders of Bellicum Pharmaceuticals, Inc. stock in Q1 2022, it is 27.27% of total holders.
Hedge funds holding Bellicum Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 83 |
|---|---|
| Q3 2017 | 86 |
| Q4 2017 | 90 |
| Q1 2018 | 90 |
| Q2 2018 | 96 |
| Q3 2018 | 100 |
| Q4 2018 | 91 |
| Q1 2019 | 91 |
| Q2 2019 | 76 |
| Q3 2019 | 61 |
| Q4 2019 | 47 |
| Q1 2020 | 24 |
| Q2 2020 | 23 |
| Q3 2020 | 18 |
| Q4 2020 | 27 |
| Q1 2021 | 23 |
| Q2 2021 | 24 |
| Q3 2021 | 21 |
| Q4 2021 | 17 |
| Q1 2022 | 22 |
Hedge funds changes in Bellicum Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 20 | 39 | 19 | 34 | -29 |
|---|---|---|---|---|---|
| Q3 2017 | 15 | 40 | 15 | 10 | 6 |
| Q4 2017 | 16 | 21 | 32 | 11 | 10 |
| Q1 2018 | 19 | 31 | 25 | 17 | -2 |
| Q2 2018 | 20 | 46 | 13 | 14 | 3 |
| Q3 2018 | 12 | 31 | 29 | 8 | 20 |
| Q4 2018 | 14 | 23 | 28 | 22 | 4 |
| Q1 2019 | 11 | 29 | 24 | 12 | 15 |
| Q2 2019 | 12 | 25 | 21 | 24 | -6 |
| Q3 2019 | 8 | 16 | 23 | 23 | -9 |
| Q4 2019 | 5 | 14 | 15 | 20 | -7 |
| Q1 2020 | 23 | 1 | 0 | 44 | -44 |
| Q2 2020 | 6 | 4 | 6 | 7 | 0 |
| Q3 2020 | 2 | 4 | 7 | 7 | -2 |
| Q4 2020 | 14 | 2 | 7 | 5 | -1 |
| Q1 2021 | 4 | 5 | 3 | 8 | 3 |
| Q2 2021 | 3 | 4 | 8 | 2 | 7 |
| Q3 2021 | 0 | 5 | 6 | 3 | 7 |
| Q4 2021 | 1 | 2 | 3 | 5 | 6 |
| Q1 2022 | 6 | 5 | 3 | 1 | 7 |
Hedge funds changes in Bellicum Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 354,000 | 2,485,000 |
|---|---|---|
| Q3 2017 | 3,593,000 | 1,894,000 |
| Q4 2017 | 1,180,000 | 1,605,000 |
| Q1 2018 | 596,000 | 1,262,000 |
| Q2 2018 | 654,000 | 1,349,000 |
| Q3 2018 | 942,000 | 314,000 |
| Q4 2018 | 38,000 | 34,000 |
| Q1 2019 | 85,000 | 95,000 |
| Q2 2019 | 31,000 | 40,000 |
| Q3 2019 | 301,000 | 33,000 |
| Q4 2019 | 324,000 | 40,000 |
| Q1 2020 | 2,408,000 | 105,000 |
| Q2 2020 | 3,747,000 | 7,000 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 0 | 0 |
| Q1 2021 | 0 | 0 |
| Q2 2021 | 0 | 0 |
| Q3 2021 | 0 | 0 |
| Q4 2021 | 0 | 0 |
| Q1 2022 | 0 | 0 |